{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:49:28Z","timestamp":1760060968301,"version":"build-2065373602"},"reference-count":21,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010573","name":"Stichting Dioraphte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022\u201001251"],"award-info":[{"award-number":["2022\u201001251"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Understanding the target site pharmacokinetics (PK) of the nitroimidazole analog DNDI\u20100690, a potential drug for the neglected parasitic disease leishmaniasis, is important due to the diversity of infected tissue sites and potential drug penetration variability. An ultrahigh\u2010performance liquid chromatography\u2013tandem mass spectrometry (UHPLC\u2010MS\/MS) method was developed and validated for quantifying DNDI\u20100690 in murine biomatrices (plasma, liver, spleen, skin, and skin microdialysate). The method used three protein precipitation sample preparation procedures, tailored for different biomatrices, utilizing a surrogate biomatrix approach. Murine tissues were enzymatically homogenized with a Collagenase A mixture. Chromatographic detection was performed on a C18 column using gradient elution, coupled to a QTRAP6500 quadrupole MS, operating in positive ionization mode. The method demonstrated accurate and precise quantification of all murine biomatrices on the surrogate biomatrix calibration standards, with a high and reproducible total recovery ranging from 75.9% to 94.2% (CV%\u2009\u2264\u20092.5%). Matrix interferences were mitigated with a deuterated internal standard. Stability experiments demonstrated that DNDI\u20100690 remained stable in all biomatrices under various conditions. This validated UHPLC\u2010MS\/MS method was successfully used to quantify DNDI\u20100690 in a target site murine infection model, demonstrating its suitability for future target site PK studies involving DNDI\u20100690.<\/jats:p>","DOI":"10.1002\/bmc.70158","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T06:28:15Z","timestamp":1750919295000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Validated LC\u2010MS\/MS Method for Quantifying the Antiparasitic Nitroimidazole DNDI\u20100690 in Preclinical Target Site PK\/PD Studies"],"prefix":"10.1002","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9052-985X","authenticated-orcid":false,"given":"Wietse\u00a0M.","family":"Schouten","sequence":"first","affiliation":[{"name":"Department of Pharmacy and Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrien","family":"van Bocxlaer","sequence":"additional","affiliation":[{"name":"Skin Research Centre, Hull York Medical School, York Biomedical Research Institute University of York  York UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwin\u00a0D.\u00a0R.","family":"Huitema","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam the Netherlands"},{"name":"Department of Pharmacology Princess M\u00e1xima Center for Pediatric Oncology  Utrecht the Netherlands"},{"name":"Department of Clinical Pharmacy, University Medical Center Utrecht Utrecht University  Utrecht the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00a0H.","family":"Beijnen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmacology Antoni van Leeuwenhoek\/The Netherlands Cancer Institute  Amsterdam the Netherlands"},{"name":"Utrecht Institute of Pharmaceutical Sciences Utrecht University  Utrecht the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jadel\u00a0M.","family":"Kratz","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases Initiative Latin America  Rio de Janeiro Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles\u00a0E.","family":"Mowbray","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases Initiative  Geneva Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas\u00a0P.\u00a0C.","family":"Dorlo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Uppsala University  Uppsala Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00436\u2010016\u20105340\u20107"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.948742"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469\u20100691.2011.03630.x"},{"key":"e_1_2_9_5_1","unstructured":"EMA.2022. \u201cICH Guideline M10 on Bioanalytical Method Validation\u2014Step 5.\u201d Accessed 09\u201002\u20102025 fromhttps:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/ich\u2010guideline\u2010m10\u2010bioanalytical\u2010method\u2010validation\u2010step\u20105_en.pdf."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.15.161"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/647939"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hct116"},{"key":"e_1_2_9_9_1","first-page":"24","volume-title":"Drug Discovery for Leishmaniasis","author":"Mowbray C.","year":"2018"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JPBA.2021.114402"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2022.123354"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2022.123494"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2024.124377"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/35016103"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01581"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000923"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpddr.2019.02.002"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13040516"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpddr.2018.01.006"},{"key":"e_1_2_9_20_1","unstructured":"WHO.2023a. \u201cGlobal Leishmaniasis Surveillance 2022: Assessing Trends Over the Past 10 Years.\u201d Accessed 07\u201002\u20102025 fromhttps:\/\/www.who.int\/publications\/i\/item\/who\u2010wer9840\u2010471\u2010487."},{"key":"e_1_2_9_21_1","unstructured":"WHO.2023b. \u201cLeishmaniasis. Key Facts.\u201d Accessed 06\u201002\u20102025 fromhttps:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/leishmaniasis."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00829\u201019"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.70158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:39:44Z","timestamp":1760038784000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.70158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1002\/bmc.70158"],"URL":"https:\/\/doi.org\/10.1002\/bmc.70158","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"type":"print","value":"0269-3879"},{"type":"electronic","value":"1099-0801"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"2025-03-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70158"}}